Multiple myeloma (MM) is a hematological malignancy that remains incurable, with relapse rates >90%. The main limiting factor for the effective use of chemotherapies in MM is the serious side effects caused by these drugs. The emphasis in cancer treatment has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted and rationally designed therapies showing greater efficacy and fewer side effects.
| INTRODUCTION
Multiple myeloma (MM) is a hematological malignancy of plasma cells localized in the bone marrow. Despite recent advances in therapy, MM remains incurable with relapse rates >90%. 1, 2 The main limiting factor for the effective use of chemotherapies in MM is the serious side effects caused by these drugs. The development of specific and targeted therapies based on nanoparticle delivery systems in MM is under investigation.
Over the last decades, a large number of nanoparticle delivery systems have been designed for cancer therapy. The emphasis in cancer treatment has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted and rationally designed therapies showing greater efficacy and fewer side effects. 3 Many drugs are hydrophobic and poorly water-soluble properties which help them to penetrate the cell membrane and reach intracellular targets; however, its therapeutic application is associated with poor absorption and low bioavailability. [4] [5] [6] [7] Therefore, nanoparticles (NPs) mainly aim to minimize drug degradation upon administration, prevent undesirable side effects, and increase drug bioavailability in the pathological area. [8] [9] [10] This review will provide an insight into the advances in nanoparticle delivery systems focused on oncology therapeutics and in particular in MM.
| NANOPARTICLE DELIVERY SYSTEMS IN CANCER
Current treatment for cancer relies on chemotherapy as a major strategy. Traditional chemotherapy has shown several disadvantages such as lack of targeting capabilities, affecting normal healthy tissues; non-specific distribution, producing systemic toxicity and side effects; low therapeutic index; and most anticancer drugs have poor water solubility. [11] [12] [13] Nanoparticle delivery systems are aimed to target higher doses of active agents into the tumor areas while sparing healthy tissues, overcoming the limitations of traditional chemotherapy. 9, 10 The delivery of anticancer drugs through a nanoparticle delivery system offers multiple attractive opportunities (Table 1) which includes (i) improved stability and delivery of poorly soluble in water drugs, permitting re-evaluation of drugs with poor pharmacokinetics, high cytotoxicity or poor cellular uptake; 14 (ii) controlled release in a specific location triggered by an specific stimuli, protection of the drug from harsh environment (acidic environment, proteases, or lysosomes of cells) extending half-life of the drug in the circulation, and controlled release over time to achieve a drug dose within a therapeutic window 10, [15] [16] [17] [18] ; (iii) targeting properties can be enhanced to deliver drugs specifically to a cell or tissue, reducing systemic side effects, increasing the concentration of the drug in the target area, and increasing therapeutic index for the chemotherapeutic agent; 19 and (iv) nanoparticle delivery systems offer a multifunctional approach to deliver combination therapy of drugs, as well as imaging agents, to improve detection, imaging, and treatment for cancer. 20, 21 Nanoparticle delivery systems are very diverse in function of shapes, sizes, and surface properties ( Figure 1 ): Liposomes are vesicles made of a bilayer of amphiphilic lipids enclosing a hydrophilic core, which can carry hydrophilic drugs within the aqueous core area while hydrophobic drugs within the hydrophobic region of the bilayer 22 ( Figure 1A ). Polymeric NPs are particles prepared from polymers; they can be biodegradable or non-biodegradable, synthetic or natural; and the drug is dissolved, entrapped, encapsulated, or attached to the matrix 23 ( Figure 1B ). Micelles are artificial vesicles similar to liposomes but made of a monolayer of amphiphilic lipids enclosing a hydrophobic core, which can carry hydrophobic anticancer agents ( Figure 1C ).
Dendrimers are repetitively branched molecules consisting of radially symmetric molecules of tree-like arms or branches ( Figure 1D ).
Polymersomes are artificial vesicles made of a bilayer of synthetic amphiphilic block copolymers enclosing a hydrophilic core, which can carry hydrophilic drugs within the aqueous core, therefore presenting a similar structure to liposomes ( Figure 1E ). Inorganic NPs are particles formed by the crystallization of inorganic salts, forming a threedimensional arrangement with linked atoms 24 ( Figure 1F ). 
| Passive targeting
Non-targeted NPs exploit passive targeting approaches taking advantage of pathophysiological conditions of the tumor microenvironment for specific delivery, such as enhanced permeation and retention (EPR) effect: Most solid tumors have blood vessels with aberrant architecture and extensive production of vascular permeability factors stimulating extravasation within tumor tissues, in addition to the lack of lymphatic drainage. Therefore, tumors exhibit enhanced vascular permeability, which will ensure a sufficient supply of nutrients and oxygen to tumor tissues for rapid growth. [25] [26] [27] The tumor vasculature is formed by poorly aligned defective endothelial cells with wide fenestrations (up to 4 μm), leading to EPR effect, which facilitates transport of macromolecules (>40 kDa) and small-sized NPs (10-400 nm) into tumors. [28] [29] [30] EPR is the gold standard technique for drug delivery systems for cancer treatment ( Figure 2 ). However, large tumors do not exhibit the EPR effect and show less accumulation of macromolecules in central areas. 31 
| Triggered targeting
A selective and controlled delivery of drugs in the tumors is still a challenge. The introduction of stimuli-responsive mechanisms to drug delivery systems helps to provide better solutions for tumor drug targeting strategies. NPs can be induced to release the drugs once in the tumor through triggered or inducible approaches. 32, 33 44, 45 or light exposure 46, 47 ) have been shown to increase the accumulation of NPs and/or enhance the release of the drugs from the NPs in the tumor ( Figure 3 ).
| Active targeting
The EPR effect and PEG stealth have improved biodistribution and circulation of nanoparticle delivery systems. Stimuli-triggered NPs Nanoparticle toxicity depends not only on their chemical composition, but also on the composition of any chemicals adsorbed onto their surfaces. 59 As a solution, the surfaces of nanoparticles can be modified to make them less harmful.
| NANOPARTICLE DELIVERY SYSTEMS FOR MYELOMA
Multiple myeloma is an incurable disease characterized by the proliferation of plasma cells in the bone marrow, 60 and represents approxi- The main limiting factor for the effective use of chemotherapies in MM is the serious side effects caused by these drugs. The use of the PIs bortezomib and carfilzomib has led to significant improvement of the survival of patients with MM. 66 However, treatment with bortezomib is limited by its neurotoxicity, especially in the peripheral nerves, which leads to sensory axonal neuropathy. 70 Carfilzomib is a second-generation proteasome inhibitor, but the safety data from a meta-analysis reported thrombocytopenia, anemia, fatigue, nausea, and diarrhea as the most common adverse events, with doselimiting neutropenia or peripheral neuropathy. 71 IMiDs are emerging promising therapies in MM which showed synergistic effects when they are added to current treatments. 69 Nevertheless, one-fourth of the patients discontinued thalidomide because of toxicity, including peripheral neuropathy, constipation, somnolence, and fatigue as common side effects. 72 Moreover, cutaneous adverse neutropenia, deep vein thrombosis, infection, and hematological cancer were observed in patients treated with lenalidomide. 73, 74 Dose-limiting neutropenia, thrombocytopenia, neuropathy, and deep vein thrombosis were common adverse effects observed in patients treated with pomalidomide. 75 Nanoparticle delivery systems offer a new strategy to increase the efficacy of the treatment and reduce side effects in normal tissues by delivering drugs to the target tissue, in this case the bone marrow niche in which myeloma cells developed. Tables 2 and 3 provide an insight into the preclinical and clinical advances in nanoparticle delivery systems used in MM.
| Non-targeted therapies
Non-targeted approaches exploit passive targeting based on the pathophysiological conditions of the myeloma microenvironment for specific delivery of the drugs. Most of the nanoparticle delivery systems that have been studied for myeloma used non-targeted NPs.
Liposomes have been used to encapsulate bortezomib, a proteasome
inhibitor with high neurotoxicity. Due to the poor water solubility of bortezomib, instead of loading the drug in the aqueous core, Free drug group showed >20% weight loss and moribundity on day 7, which led to required killing of the mice. In case of liposomal bortezomib NPs, there was <10% loss in body mass during the 2-week study period 77 (Table 2) . However, even though reduced side effects, distribution studies should have been performed to verify the location of the NPs.
Liposomes have been also used for incorporation of antiestrogens to prevent oral administration of an anti-estrogen being widely distributed to the whole body and reaching un- (Table 2) . with bortezomib monotherapy (median TTP=6.5 months) [79] [80] [81] ( NPs were more potent than free drug-sensitizing leukemic cells to TNF-α and paclitaxel-induced apoptosis 84 (Table 2 ). However, this study is very preliminary, only in vitro studies were realized. In vivo studies to prove efficacy and distribution will demonstrate the potential of thymoquinone NPs in myeloma.
Other polymeric NPs that are nanocolloids based on N,N,Ntrimethyl chitosan have been developed to encapsulate camptothecin, a potent anticancer agent of plant origin, which is extremely water-insoluble. 85 In vitro cytotoxicity showed no statistical difference between loaded nanocolloids and free drug. However, loaded nanocolloids more effectively inhibited tumor growth and prolonged survival time than free drug in vivo. In this case, the murine BALB/c myeloma model was treated with i.v. injections of loaded nanocolloids (2.5 mg/kg), free drug (2.5 mg/kg), or nanocolloids (25 mg/kg) every 3 days for 15 days 86 (Table 2 ). Further studies of distribution and systemic toxicities should be examined. (Table 2 ). However, this study is very preliminary, only in vitro studies were realized. In vivo studies to confirm improved the stability of carfilzomib, and efficacy, and distribution
of the micelles will demonstrate the potential of this approach in myeloma.
4.
Inorganic NPs have been developed for the treatment for myeloma.
Silica NPs have been combined with snake venom from Walterinnesia aegyptia, a natural toxin with antitumor potential. 89 The particle size was 300 nm, and the combination of the silica NPs with the snake venom was tested on cells from five patients with myeloma and XG2 cell line. This combination decreased viability and induced apoptosis. 90 In a follow-up, publication-enhanced anticancer effi- (Table 2) . Nonetheless, distribution of these NPs, effect on CD138+ non-stem cell-like tumors, and systemic toxicities should be investigated.
The main disadvantages of non-targeted NPs are associated with problems in pharmacokinetic and pharmacodynamics, including their dependency on abnormal leakiness of blood vessels and lack of specificity. Therefore, new techniques are needed to improve the accumulation of NPs at the disease site.
| Triggered therapies
The combination of magnetic hyperthermia treatment through magnetic NPs and remote control drug release from the same NPs using heat as the trigger to release the drugs has been used in MM.
Doxorubicin magnetically responsive NPs were injected intratumorally (i.t.) 5 mg/kg (0.13 mg/kg doxorubicin equivalent) into mice bearing subcutaneous xenograft tumors and then exposed to the magnetic field. Combination of chemotherapy and magnetic hyperthermia NPs decreased tumor volume gradually, until reaching zero tumor volume at day 45 without further recurrence 94 (Table 2 ). In addition, no significant toxicity was found. These results with i.t injection showed promising results, i.v injection as more general approach and related distribution should be tested in the future. One limitation of this approach is the ability to treat only the tumor site with well-defined localization in case of further clinical evaluation.
| Targeted therapies
In general, targeted NPs used the same nanoparticle delivery systems of non-targeted therapies, but in this case NPs contain a targeted ligand to help NPs to be directed toward tumor cells, tumor blood vessel endothelial cells, or the tumor microenvironment. The strategies used in MM to date are follows:
F I G U R E 4 Schematic of active (targeted) nanoparticles in cancer.
Nanoparticles extravasate from the vasculature due to the enhanced permeation and retention (EPR) effect, then targeted nanoparticles bind and internalize into tumor tissues, the retention and uptake of these nanoparticles in cancer cells (brown) is augmented due to the specific antigen-antibody/ligand-receptor interactions, and wash out of nanoparticles is reduced Free drug group showed >15% weight loss and moribundity on day 7, which led to required killing of the mice. In case of targeted NPs, there was around 10% loss in body mass. Targeted NPs demonstrated enhancement in tumor growth inhibition compared to non-targeted NPs, as well as significant higher accumulation in the tumor 97 ( Table 2) .
T A B L E 2 Preclinical nanoparticle delivery systems in multiple myeloma

Very Late Antigen-4 (VLA-4) is an integrin
Another study has developed liposomal carfilzomib NPs, such as the ones previously described for bortezomib, 77 The most common toxicities were grade 3. The overall response rate was 88%: 12% CR.TPP was 23.1 months, with 2-year and 3-year progression-free survival rates of 42% and 23%, respectively.
The patient survival rate at 3 years was 67%
Hussein et al. 82 PegLD, PEGylated liposomal doxorubicin; MTD, maximum tolerated dose; CR, complete response; PR, partial response; TTP, time to progression.
| 537
de la PUeNTe aNd aZaB personalized medicine approach will be required in case of clinical approach. (Table 2 ).
ATP-binding cassette (ABC) drug transporters
Targeted CSC therapy using mAb in combination with nanoparticle delivery systems is a promising strategy to target MM CSCs for patients with refractory MM. This is because the therapeutic strategy has the specific action on the MM CSCs and the proven therapeutic efficacy at lower drug dosages as well as preventing the paclitaxel efflux from cells for generating the cytotoxic effects on the MM CSCs. Further investigation is required in this promising targeted approach. (Table 2) . Nonetheless, non-significant differences were found between targeted and non-targeted NPs. The study showed that bortezomib, as a pretreatment regimen, modified the bone microenvironment, and loaded NPs enhanced survival and decreased tumor burden. However, biodistribution studies in organs such as lung, liver, and kidney should be tested, and the reduction in offside effects provided. 
| FUTURE DIRECTIONS
| Challenges of NPs for MM treatment
The EPR effect is an important factor for delivery of nanoparticle systems in general, which has been confirmed mainly for solid tumors.
Although encouraging results have been shown with liposomes, polymeric NPs, micelles, and inorganic NPs using non-targeted approaches, 82, 86, 88, 93 MM is a hematological malignancy and it is still not clear that the EPR effect will have a role in how non-targeted NPs exploit passive targeting based on the pathophysiological conditions of the myeloma microenvironment.
Targeted approaches containing targeted ligands against a marker or receptor overexpressed in the targeted tumor cells are challenging in MM. The characterization of MM by a single surface marker is being questioned over the last decade. CD138, the gold standard surface marker to detect MM cells, is shown to be affected by drug exposure and hypoxia. 110 Other secondary antibodies used in combinations such as CD38, CS1, and CD20 are highly expressed in many other cell types. 111 Other markers such as VLA4-4 is expressed in several cell types, and the expression in MM cells is very heterogeneous. 97, 100 The lack of a constitutively expressed unique surface marker in MM limits the specific active targeting of NP systems.
In addition, myeloma is a complex disease involving multiple pathways and mutations. Inhibition of a pathway by a single drug may be insufficient to achieve therapeutic efficacy. As a result, combination therapy will let to use drugs at lower doses, reducing cytotoxic effects but increasing efficacy due to the synergistic effect of several agents targeting different pathways. 112 The effectivity of combination therapy by NPs will depend on the ability of NPs to carry multiple therapeutic agents with different physicochemical properties and pharmacological behaviors, which adds more challenges to the technical development of NPs in MM.
| Strategies to improve NPs for MM treatment
Nanoparticles offer multifunctionality, combining both diagnostics and therapeutics, combination known as theranosis. For successful theranosis, the efficient delivery of imaging agents and drugs is critical to provide sufficient imaging signal or drug concentration in the targeted disease site. 113, 114 This will allow for monitoring drug delivery and image-guided therapy of the target site. In addition, the investigation of new molecular targets will help the ability to improve delivery at the tumor level. These benefits could include advances in detection, imaging, and treatment for myeloma. On the other hand, NPs can be designed to target multiple antitumor moieties at the same time to maximize the accuracy of tumor targeting. In this case, further investigation of myeloma cell surface markers is required to identify alternative targets with adequate expression levels.
Another consideration will be to contemplate the disadvantages of current in vitro testing techniques to effectively evaluate the behavior of nanoparticle delivery systems. The discrepancy between preclinical and clinical outcomes can be attributed to the failure of classic two-dimensional culture models to accurately recapitulate the complex biology of MM and drug responses observed in patients. Threedimensional (3D) culture systems are gaining strength as in vitro systems to assess and predict drug sensitivity in myeloma. [115] [116] [117] 3D in vitro systems could help to evaluate NPs as drug delivery systems and predict better the in vivo performance of NPs.
In summary, the promising results in myeloma preclinical studies will lead to further investigation, and in a short period of time, nanoparticle-based therapies will undergo more clinical investigation.
Safety of these devices will be an important consideration before moving forward. Therefore, there remains much to be learned in the emerging field of nanomedicine in myeloma.
| CONCLUSIONS
The main limiting factor for the effective use of chemotherapies in MM is the serious side effects caused by these drugs. and clinical studies will lead to further investigation. Therefore, there remains much to be learned in the emerging field of nanomedicine in myeloma.
